Here is some long awaited news on MBHS, This company is going to explode in the am.Imo it was a bargin to get in on this one at $0.22- 0.24. I think the news of the company targeting international markets is a great step foward especially in Russia where the early dectection rate is extremley low. This one should be trading back up to $0.33-0.38 or higher. Stock has shown some great volume and some price apprecation. I am including the news for you to read more about the company. Good luck in the am and happy trading!!
TEL AVIV, Israel, July 30, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced a strategy of targeting new international market opportunities. In particular, the company has identified the emerging markets of Russia and Commonwealth of Independent States (CIS)
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.
According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
mBeach CEO Yossi Biderman commented, "One of the main reasons for relatively high cancer death rates in Russia and CIS is that patients are often diagnosed with the disease once it is too late. This is a very large and growing healthcare market and represents an important opportunity for Skin Cancer Scanning (SCS), our wholly owned subsidiary company. Our simple-to-use, non-invasive, point-of-care, skin cancer detection solution is ideally suited for this market."
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.